SLS
NASDAQSELLAS Life Sciences Group Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$8.22+2.67 (+48.11%)
2026-03-042026-06-05
News · 26 weeks29-86%
2025-12-142026-06-07
Mix1690d
- SEC Filings9(56%)
- Other7(44%)
Latest news
25 items- SECSELLAS Life Sciences Group Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)
- PRSELLAS Life Sciences to Participate in Upcoming Investor ConferencesNEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS, will participate in the following upcoming investor conferences: 2026 Stifel Virtual Targeted Oncology ForumFormat: Corporate Presentation and Fireside ChatDate and Time: Tuesday, May 19, 2026, at 2:00 PM ETLocation: New York, NYWebcast Link: Click here A.G.P.'s Annual Virtual Healthcare ConferenceFormat: Fireside Chat Date: Wednesday, May
- SECSELLAS Life Sciences Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)
- PRSELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update– Contract Research Organization for the Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) Informed the Company that 78 Events have Occurred in the Trial as of May 11, 2026; SELLAS Remains Blinded to Trial Outcomes – – Final Analysis of REGAL Trial of GPS in AML to be Conducted Following the 80th Event – – Ongoing Dosing of Patients in Phase 2 Trial of SLS009 in Newly Diagnosed First Line AML – – $107.1 Million in Cash and Cash Equivalents as of March 31, 2026; Additional $7.5 Million in Proceeds Received in Q2 2026 to Date through Warrant Exercises – NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or
- SECSEC Form 10-Q filed by SELLAS Life Sciences Group Inc.10-Q - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by SELLAS Life Sciences Group Inc.SCHEDULE 13G/A - SELLAS Life Sciences Group, Inc. (0001390478) (Subject)
- SECSEC Form DEFA14A filed by SELLAS Life Sciences Group Inc.DEFA14A - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)
- SECSEC Form DEF 14A filed by SELLAS Life Sciences Group Inc.DEF 14A - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by SELLAS Life Sciences Group Inc.SCHEDULE 13G/A - SELLAS Life Sciences Group, Inc. (0001390478) (Subject)
- SECSEC Form S-3ASR filed by SELLAS Life Sciences Group Inc.S-3ASR - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)
- SECSELLAS Life Sciences Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)
- PRSELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update– Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Final Analysis upon Reaching 80 Events – – First Patient Dosed in Phase 2 Trial of SLS009 in Newly Diagnosed First Line AML – – Reported Positive Phase 2 Data of SLS009 in Relapsed/Refractory (r/r) AML at ASH 2025 – – $71.8 Million in Cash and Cash Equivalents as of December 31, 2025; Additional $42.6 Million in Proceeds Received in Q1 2026 to Date Through Warrant Exercises – NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of nov
- SECSEC Form 10-K filed by SELLAS Life Sciences Group Inc.10-K - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)
- PRSELLAS Life Sciences to Present Preclinical Data Highlighting Potent Activity of SLS009 in AML at the 2026 AACR ConferenceNEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that preclinical data on SLS009 (tambiciclib), a potent, selective CDK9 inhibitor, will be presented in a poster session at the American Association for Cancer Research (AACR) taking place April 17-22 at San Diego Convention Center in San Diego, CA. The abstracts will be published in the online Proceedings of the AACR. Exposure of acute myeloid leukemia (AML) cell lines to increasing concentrations of SLS009 for 6 hours r
- PRSELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009- Study to Enroll 80 Patients Unlikely to Benefit from Venetoclax/Azacitide (Aza/Ven) Therapy in the US and Europe -- SELLAS' Predictive Biomarker and AI Assisted Precision Medicine Models to be Utilized -- Topline Data Expected in Q4 2026 – NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the first patient has been enrolled in its randomized Phase 2 trial evaluating SLS009 (tambiciclib), a highly selective CDK9 inhibitor in newly diagnosed, first-line acute myeloid leuk
- SECSELLAS Life Sciences Group Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by SELLAS Life Sciences Group Inc.SCHEDULE 13G/A - SELLAS Life Sciences Group, Inc. (0001390478) (Subject)
- PRSELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into EuropeSupports capital-efficient expansion of the SLS009 clinical program into frontline AML, enabling broader U.S. and European patient enrollment U.S. enrollment evaluating SLS009 in combination with AZA/VEN in newly diagnosed AML with high-risk features is planned for Q1 2026, with European enrollment anticipated in Q2 2026 NEW YORK, Jan. 14, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that it has entered into an agreement with IMPACT-AML, a European collaborative initiative dedicated t
- INSIDERDirector Varian John was granted 50,000 shares, increasing direct ownership by 218% to 72,900 units (SEC Form 4)4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)
- INSIDERDirector Van Nostrand Robert L was granted 50,000 shares, increasing direct ownership by 152% to 82,900 units (SEC Form 4)4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)
- INSIDERDirector Scheinberg David A was granted 50,000 shares, increasing direct ownership by 217% to 73,082 units (SEC Form 4)4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)
- INSIDERSVP, Chief Development Officer Cicic Dragan was granted 300,000 shares, increasing direct ownership by 116% to 557,805 units (SEC Form 4)4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)
- INSIDERCFO Burns John Thomas was granted 300,000 shares, increasing direct ownership by 118% to 554,327 units (SEC Form 4)4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)
- INSIDERDirector Kalin Katherine Bach was granted 50,000 shares, increasing direct ownership by 48% to 154,400 units (SEC Form 4)4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)
- INSIDERDirector Wasman Jane was granted 50,000 shares, increasing direct ownership by 117% to 92,900 units (SEC Form 4)4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)
SLS FAQ
6 questionsWhat does SELLAS Life Sciences Group Inc. do?
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a wilms tumor 1 targeting peptide-based cancer immunotherapeutic agent, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It also develops nelipepimut-S, a cancer immunotherapy that is in Phase 2b clinical trials for the treatment of early stage...Where does SLS stock trade?
SELLAS Life Sciences Group Inc. (SLS) is listed on NASDAQ.What sector and industry is SLS in?
SELLAS Life Sciences Group Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about SLS?
SELLAS Life Sciences Group Inc. has had 1 recent analyst action on file. The most recent action was from Cantor Fitzgerald: Overweight with a $1800.00 price target on 2021-07-21. Recent price targets cluster around $1800.00.What companies are similar to SLS?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare SLS side-by-side with any of them on Quantisnow.How can I track SLS on Quantisnow?
Quantisnow aggregates SELLAS Life Sciences Group Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SLS to receive live email and push alerts on every new disclosure.